News|Articles|November 20, 2026 (Updated: November 20, 2026)

5 Pancreatic Cancer Numbers Patients and Families Should Know

Listen
0:00 / 0:00

Key Takeaways

  • An estimated 67,530 U.S. diagnoses in 2026 (~3% of cancers) supports referral considerations to high-volume pancreatic centers and use of second opinions for complex treatment sequencing.
  • A 13% five-year relative survival rate reflects an all-comers, stage-agnostic population metric and should not be applied as an individualized survival prediction or a fixed life-expectancy estimate.
SHOW MORE

On World Pancreatic Cancer Day, here are five numbers from the American Cancer Society's 2026 report that people with pancreatic cancer and their families should understand, and what those numbers can and cannot say about one person's outlook.

Thursday, Nov. 19, was World Pancreatic Cancer Day, which falls during Pancreatic Cancer Awareness Month. If you or someone you love has pancreatic cancer, you have probably run into statistics, often when you were least ready for them. Numbers can feel frightening, but understood in context they can also help you ask better questions about your own care.

Here are five figures from the American Cancer Society's yearly report, "Cancer Statistics, 2026," published in January 2026 in CA: A Cancer Journal for Clinicians, along with what each one means, and does not mean, for people living with the disease.

1. About 67,530 Americans Are Expected to Be Diagnosed This Year

The report estimates that 67,530 people in the United States will be diagnosed with pancreatic cancer in 2026. That is about 3% of all cancer diagnoses, so it is far less common than breast, prostate, lung or colorectal cancer.

Being less common can make a diagnosis feel isolating. It also means it is worth asking whether your care team treats many people with pancreatic cancer, or whether a second opinion at a center that does would help you weigh your options.

2. The Overall Five-Year Survival Rate Is 13%

The five-year relative survival rate for pancreatic cancer is 13%, the third year in a row it has stayed at that level, according to the report. By comparison, the rate for all cancers combined has reached 70%.

A "five-year relative survival rate" compares people with a cancer to people of the same age in the general population. It is an average across everyone diagnosed, at every stage and every level of health. It is not a prediction for you, and it does not mean people live only five years. It counts how many people are still alive five years after diagnosis, and many of them live longer.

3. Stage at Diagnosis Changes the Outlook

Only 17% of people are diagnosed while the cancer is still localized, meaning it has not spread beyond the pancreas. For that group, five-year survival is 44%, more than three times the overall rate.

That is one reason doctors focus so closely on whether a tumor is resectable, meaning it can be removed with surgery such as a Whipple procedure. If you are not sure what stage your cancer is, or whether surgery is possible now or after chemotherapy, ask your oncologist to walk you through it.

4. Pancreatic Cancer Is the Third Leading Cause of Cancer Death

An estimated 52,740 people will die of pancreatic cancer in 2026, making it the third leading cause of cancer death in the U.S. among both men and women, behind lung and colorectal cancers. Advocacy groups note it is the only major cancer with a five-year survival rate below 20%.

This number explains why researchers and advocates are pushing so hard for better treatments. For you, it is a reason to ask about palliative care, which is specialized care for symptoms like pain, weight loss and fatigue. Palliative care can start at diagnosis, alongside treatment meant to control the cancer. It is not the same as hospice.

5. Today's Statistics Lag Behind Today's Treatments

Survival statistics are built from people who were diagnosed years ago, so they cannot reflect treatments that have become available since. In 2026, the FDA approved Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, and CURE has shared how one patient moved from chemotherapy to Rasonque. Other research, such as a study of a device called Optune Pax that delayed pain in locally advanced pancreatic cancer, is focused on helping people feel better while they live with the disease.

Clinical trials are another path. Many experts encourage people with pancreatic cancer to ask about trials early, at diagnosis and again whenever treatment changes, rather than waiting until other options run out.

Statistics describe groups, and people are individuals. Survivors such as Dan, who shared his path from stage 4 to survivor, are a reminder that every number has people on both sides of it. Your own outlook depends on your stage, your tumor's features, your overall health and how you respond to treatment, and your care team is the best source for what the numbers mean for you.

References

  1. "Cancer Statistics, 2026." American Cancer Society. CA: A Cancer Journal for Clinicians. January 2026.
  2. "Cancer Facts & Figures 2026." American Cancer Society. January 2026.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.


Related to this article

Image of of hot flashes
Hot flashes are common during and after breast and prostate cancer treatment. Here is how hormone treatments compare with the nonhormonal medicines, therapies and comfort steps that national guidelines list, and why the right choice depends on your cancer.